TBC Roche Products Pty Ltd
Product name
TBC
Sponsor
Accepted date
May-2024
Active ingredients
inavolisib
Proposed indication
For the treatment of adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Application type
A (new medicine)
Publication date
May-2024